Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.60 |
| ▸ | AKT2 | P31751 | 20/20 | 0.60 |
| ▸ | AKT3 | Q9Y243 | 20/20 | 0.60 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.56 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12211127 | 0.95 | AKT1 (0.56) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL927111 | 0.90 | AKT1 (0.60) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL925482 | 0.90 | AKT1 (0.60) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL2367614 | 0.90 | AKT1 (0.60) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL191524 | 0.90 | AKT1 (0.60) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL25230276 | 0.90 | AKT1 (0.60) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL2367210 | 0.86 | AKT1 (0.60) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL16250566 | 0.84 | AKT1 (0.53) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL12194050 | 0.84 | AKT1 (0.53) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL192707 | 0.83 | AKT1 (0.55) | AKT1AKT2AKT3PIK3CAPRKG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023109540-A1 | HETEROCYCLIC COMPOUND WITH AKT KINASE INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2023-06-22 | — | — | WO | disclosed |
| WO-2019173516-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-09-12 | — | — | WO | disclosed |
| US-9610289-B2 | Combinations of AKT inhibitor compounds and erlotinib, and methods of use | GENENTECH, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20170065588-A1 | BIOMARKERS FOR PREDICTING SENSITIVITY TO CANCER TREATMENTS | GENENTECH INC (US) | 2017-03-09 | — | — | US | disclosed |
| US-20160051550-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ERLOTINIB, AND METHODS OF USE | GENENTECH, INC. (US) | 2016-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160051550-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ERLOTINIB, AND METHODS OF USE | AKT1, AKT2, MTOR | AKT1 1/4885AKT2 2/4885AKT3 5/4885 |
| US-20170065588-A1 | BIOMARKERS FOR PREDICTING SENSITIVITY TO CANCER TREATMENTS | TP53, TSG101, CD44 | AKT1 2481/4885AKT2 2132/4885AKT3 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.